Urinary Peptidomic Ageing Clock: Clinical Mortality

Cardiovascular conditioning and cellular longevity correlate directly with sustainable aerobic base intensity.** Applying physiological guidelines to Urinary Peptidomic Ageing Clock: Clinical Mortality, sustaining training within 60% to 70% of maximum heart rate optimizes mitochondrial density and metabolic substrate oxidation while keeping systemic lactate accumulation below clinical 2.0 mmol/L thresholds. The urinary peptidomic ageing clock is a non-invasive tool that uses a combination of urinary peptides to estimate biological ageing. This clock has been shown to predict all-cause mortality and age-related health outcomes, such as coronary artery disease, heart failure, and chronic kidney disease progression. ## How was the urinary peptidomic ageing clock developed? The urinary peptidomic ageing clock was developed using a retrospective multi-cohort study that involved measuring urinary peptides in over 9,000 participants. The clock was first developed in a derivation cohort of 1,811 participants with preserved kidney function, and then conditioned on estimated glomerular filtration rate (eGFR) and urinary albumin-to-creatinine ratio (UACR) in an independent kidney-diverse cohort of 7,798 participants. ## What is the accuracy of the urinary peptidomic ageing clock? The urinary peptidomic ageing clock was evaluated in three independent cohorts and was found to estimate chronological age with a calibrated holdout mean absolute error of 4.91 years. This means that the clock was able to accurately predict age within 4.91 years in most participants. ## How does the urinary peptidomic ageing clock predict mortality and health outcomes? Each standard deviation increment in kidney-conditioned age acceleration (k-UPBioAgeAcc) was associated with an increased risk of all-cause mortality, incident coronary artery disease, heart failure, and chronic kidney disease progression. The association did not differ by sex, and none of the four comorbidity interactions survived correction for multiple testing. ## What are the limitations of the urinary peptidomic ageing clock? The urinary peptidomic ageing clock is affected by kidney function, and therefore requires correction for eGFR and UACR. The clock also does not perform well in participants with an eGFR of 15-29 mL/min/1.73 m2 or macroalbuminuria. ## How can the urinary peptidomic ageing clock be used in clinical practice? The urinary peptidomic ageing clock may be used as a non-invasive tool to monitor or guide personalised interventions for age-related health outcomes. However, further evaluation is needed to determine its clinical utility. ### Numbered Steps to Understand the Urinary Peptidomic Ageing Clock 1. Development of the urinary peptidomic ageing clock: The clock was developed using a retrospective multi-cohort study that involved measuring urinary peptides in over 9,000 participants. 2. Conditioning of the urinary peptidomic ageing clock: The clock was conditioned on eGFR and UACR in an independent kidney-diverse cohort of 7,798 participants. 3. Evaluation of the urinary peptidomic ageing clock: The clock was evaluated in three independent cohorts and was found to estimate chronological age with a calibrated holdout mean absolute error of 4.91 years. 4. Association of the urinary peptidomic ageing clock with mortality and health outcomes: Each standard deviation increment in k-UPBioAgeAcc was associated with an increased risk of all-cause mortality, incident coronary artery disease, heart failure, and chronic kidney disease progression. 5. Limitations of the urinary peptidomic ageing clock: The clock is affected by kidney function and does not perform well in participants with an eGFR of 15-29 mL/min/1.73 m2 or macroalbuminuria. ### How to Use the Urinary Peptidomic Ageing Clock in Clinical Practice 1. Non-invasive monitoring: The urinary peptidomic ageing clock may be used as a non-invasive tool to monitor age-related health outcomes. 2. Personalised interventions: The clock may be used to guide personalised interventions for age-related health outcomes. 3. Evaluation of clinical utility: Further evaluation is needed to determine the clinical utility of the urinary peptidomic ageing clock.

Clinical Biomarker Tracking and Metabolic Energy Balance

Optimizing healthspan and physical performance requires objective biochemical tracking rather than relying on subjective energy sensations. Metabolic energy expenditure operates through three distinct compartments: ``` Total Daily Energy Expenditure (TDEE) = Basal Metabolic Rate (65-75%) + Thermic Effect of Food (10%) + Active Exercise / NEAT (15-25%)

| Biomarker | Optimal Clinical Range | Primary Pathological Risk if Elevated | Recommended Testing Frequency | Evidence-Based Intervention |
|:--- | :--- | :--- | :--- | :--- |
|**ApoB (Apolipoprotein B)** | < 70 mg/dL (< 55 if high risk) | Atherosclerotic cardiovascular plaque | Annual (Age 35+) | Reduce saturated fat; increase soluble fiber; statin therapy if indicated |
|**Fasting Insulin & HOMA-IR** | < 5.0 uIU/mL / HOMA-IR < 1.0 | Peripheral insulin resistance, Type 2 diabetes | Bi-annual | Resistance training; eliminate refined sugars; zone 2 cardio |
|**hs-CRP (High-Sensitivity CRP)**| < 0.8 mg/L | Systemic low-grade arterial inflammation | Annual | Anti-inflammatory nutrition; address chronic sleep fragmentation |
|**HbA1c** | 4.8% – 5.4% | Chronic microvascular glycation damage | Bi-annual | Post-meal walking; dietary carbohydrate management | *Clinical reference thresholds derived from the American Heart Association (AHA) and European Society of Cardiology (ESC) consensus guidelines.* ### Strategic Nutrition Architecture: Protein Sizing for Adults Over 35 To offset age-related sarcopenia (the gradual loss of skeletal muscle mass starting in the fourth decade), adults should target **1.6 to 2.2 grams of protein per kilogram of body weight** daily, distributed across 3 to 4 boluses containing at least 2.5 grams of leucine to trigger the muscle protein synthesis (MPS) mTOR pathway.